Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer To Merge Off-Patent Business With Mylan

Executive Summary

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

You may also be interested in...



Former Mylan Executive Faces Jail After Pleading Guilty To Insider Trading

A six-year Mylan employee, Dayakar Mallu, is facing up to six years in jail after pleading guilty to insider trading and tax offence charges.

COVID-19 Alters But Doesn’t Change M&A Machine In 2020

Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.

A Year Of Surprises Shakes Up Off-Patent Industry

After an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly compiled global sales ranking.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel